When the President of the United States declares an emergency or disaster under either the Stafford Act or the National Emergencies Act, in conjunction with the Secretary of the U.S. Department of Health and Human Services’ declaration of a public health emergency...

As coverages and regulations continue to broaden, often on a day-to-day basis, guidelines related to the COVID-19 pandemic frequently open up additional factors to consider – for instance, issues with homebound patients.

The use of telehealth is ramping up as a result of the COVID-19 pandemic because fewer patients are visiting a doctor's office for treatment of various conditions. Now, the latest arrest in connection with an alleged $410 million healthcare fraud scheme serves as...

The healthcare system is facing an unprecedented crisis, but accurate COVID-19 coding and billing can help providers weather the storm and prepare for future outbreaks.

During the Talk Ten Tuesdays weekly Internet radio broadcast last week, we received many questions which we never got to answer. I am going to share some of those answers with you now.

Maryland Attorney General Brian E. Frosh today warned health care providers against collecting or billing for patient copays, coinsurance, or deductibles for costs related to COVID-19 testing. In a letter to the Maryland Board of Physicians and MedChi, the state medical society, Attorney General Frosh reminds...

When the first guidance on COVID-19 testing was released on March 13, CMS made it clear that there would be no beneficiary cost obligations for the COVID-19 test. This, though, was simply a basic tenet of the Medicare payment system; there is never beneficiary coinsurance or deductibles on approved lab tests.

Telehealth usage was on the rise even before the COVID-19 coronavirus pandemic, according to a new survey from the American College of Physicians (ACP).

Biomedical innovators have mobilized across the world to address COVID-19, from the initiation of clinical trials for potential vaccines to ongoing studies of repurposed medications for potential therapeutic and prophylactic benefit. Most policy commentary for therapeutic development has focused on issues such the availability of master...